{
    "organizations": [],
    "uuid": "c4bfe41d7f36ea3a5e79fcbaeae7f9c269ddc575",
    "author": "",
    "url": "https://www.reuters.com/article/brief-theravance-biopharma-says-fda-has/brief-theravance-biopharma-says-fda-has-approved-an-expanded-indication-for-trelegy-ellipta-idUSFWN1S20YC",
    "ord_in_thread": 0,
    "title": "BRIEF-Theravance Biopharma Says FDA Has Approved An Expanded Indication For Trelegy Ellipta",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Theravance Biopharma Inc:\n* THERAVANCE BIOPHARMA HIGHLIGHTS APPROVAL OF EXPANDED INDICATION IN THE US FOR ONCE-DAILY TRELEGY ELLIPTA FOR TREATMENT OF COPD PATIENTS\n* THERAVANCE BIOPHARMA INC - U.S. FDA HAS APPROVED AN EXPANDED INDICATION FOR TRELEGY ELLIPTA\n* THERAVANCE BIOPHARMA INC - EXPANDED APPROVAL IN U.S. ALLOWS TRELEGY ELLIPTA TO BE USED AS A TREATMENT FOR A BROADER POPULATION OF COPD PATIENTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T15:46:00.000+03:00",
    "crawled": "2018-04-25T16:11:49.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "theravance",
        "biopharma",
        "inc",
        "theravance",
        "biopharma",
        "highlight",
        "approval",
        "expanded",
        "indication",
        "u",
        "trelegy",
        "ellipta",
        "treatment",
        "copd",
        "patient",
        "theravance",
        "biopharma",
        "inc",
        "fda",
        "approved",
        "expanded",
        "indication",
        "trelegy",
        "ellipta",
        "theravance",
        "biopharma",
        "inc",
        "expanded",
        "approval",
        "allows",
        "trelegy",
        "ellipta",
        "used",
        "treatment",
        "broader",
        "population",
        "copd",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}